Corvus Pharmaceuticals Inc
CRVSHealthcare|Biotechnology|USA
$15.67
-0.53 (-3.27%)
Tangible Book
$2.86
Earnings Power
$2.59
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06561048 Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | P3 | Recruiting | 150 | RCT, Open-label | Soquelitinib, Belinostat, Pralatrexate |
| NCT07441395 Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Atopic Dermatitis, Atopic Dermatitis Eczema | P2 | Recruiting | 200 | RCT, Double-blind | Soquelitinib, Placebo |
| NCT03952078 A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | T-cell Lymphoma | P1 | Active | 151 | Open-label | CPI-818 |
| NCT04734873 CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients | Covid-19 | P3 | Terminated | 46 | RCT, Double-blind | CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC |
| NCT03237988 Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects | Healthy Subjects | P1 | Completed | 24 | RCT, Open-label | CPI-444 Capsules, CPI-444 Tablets |
| NCT04464395 Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients | COVID-19 | P1 | Completed | 30 | Open-label | CPI-006 |
| NCT04280328 Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Completed | 7 | Open-label | Ciforadenant, daratumumab |
| NCT03454451 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Non-Small Cell Lung Cancer, Renal Cell Cancer | P1 | Completed | 117 | RCT, Open-label | CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab |
| NCT06345404 Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD | Atopic Dermatitis | P1 | Completed | 82 | RCT, Double-blind | Soquelitinib, Placebo |
| NCT02655822 Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer | P1 | Completed | 502 | RCT, Open-label | Ciforadenant, Ciforadenant, Ciforadenant, Ciforadenant + atezolizumab, Ciforadenant |